BIOMAT Database Logo BIOMAT Database Logo

Interferon-alpha therapy for chronic active Epstein-Barr virus infection: potential effect on the development of T-lymphoproliferative disease. 1998

Y Sakai, and S Ohga, and Y Tonegawa, and H Takada, and F Nakao, and H Nakayama, and T Aoki, and S Yamamori, and T Hara
Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

OBJECTIVE A patient with aggressive chronic active Epstein-Barr virus (CAEBV) infection is described whose disease activity subsided after interferon (IFN)-alpha therapy. METHODS The patient had intermittent fever, cytopenia, liver dysfunction, hepatosplenomegaly, abnormal titers of EBV-associated antibodies, and positive EBV genomes. RESULTS Despite repeated trials of the antiviral agents prednisolone and gamma-globulin, his condition deteriorated. The administration of IFN-alpha (1 x 10(5) U/kg subcutaneously 3 times per week) led to a dramatic clinical improvement. During the IFN-alpha therapy, the rearrangement bands of T-cell antigen receptor genes disappeared assessed by Southern blotting with a decrease in the number of activated T cells, although the EBV-genome remained evident. CONCLUSIONS These observations suggest that IFN-alpha is useful in managing CAEBV, possibly restraining the clonal development of T-lymphoproliferative disease (LPD) and EBV-associated B-LPD, although it does not eradicate the proliferation of EBV.

UI MeSH Term Description Entries
D007244 Infectious Mononucleosis A common, acute infection usually caused by the Epstein-Barr virus (HERPESVIRUS 4, HUMAN). There is an increase in mononuclear white blood cells and other atypical lymphocytes, generalized lymphadenopathy, splenomegaly, and occasionally hepatomegaly with hepatitis. Glandular Fever,Mononucleosis, Infectious,Fever, Glandular
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008232 Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified. Duncan's Syndrome,X-Linked Lymphoproliferative Syndrome,Duncan Disease,Epstein-Barr Virus Infection, Familial Fatal,Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males,Familial Fatal Epstein-Barr Infection,Immunodeficiency 5,Immunodeficiency, X-Linked Progressive Combined Variable,Lymphoproliferative Disease, X-Linked,Lymphoproliferative Syndrome, X-Linked, 1,Purtilo Syndrome,X-Linked Lymphoproliferative Disease,X-Linked Lymphoproliferative Disorder,Disease, Duncan,Disease, X-Linked Lymphoproliferative,Diseases, X-Linked Lymphoproliferative,Disorder, Lymphoproliferative,Disorder, X-Linked Lymphoproliferative,Disorders, Lymphoproliferative,Disorders, X-Linked Lymphoproliferative,Epstein Barr Virus Induced Lymphoproliferative Disease In Males,Epstein Barr Virus Infection, Familial Fatal,Familial Fatal Epstein Barr Infection,Immunodeficiency 5s,Immunodeficiency, X Linked Progressive Combined Variable,Lymphoproliferative Disease, X Linked,Lymphoproliferative Diseases, X-Linked,Lymphoproliferative Disorder,Lymphoproliferative Disorder, X-Linked,Lymphoproliferative Disorders, X-Linked,Lymphoproliferative Syndrome, X-Linked,Lymphoproliferative Syndromes, X-Linked,Purtilo Syndromes,Syndrome, Purtilo,Syndrome, X-Linked Lymphoproliferative,Syndromes, Purtilo,Syndromes, X-Linked Lymphoproliferative,X Linked Lymphoproliferative Disease,X Linked Lymphoproliferative Disorder,X Linked Lymphoproliferative Syndrome,X-Linked Lymphoproliferative Diseases,X-Linked Lymphoproliferative Disorders,X-Linked Lymphoproliferative Syndromes
D008297 Male Males
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004854 Herpesvirus 4, Human The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. Burkitt Herpesvirus,Burkitt Lymphoma Virus,E-B Virus,EBV,Epstein-Barr Virus,Human Herpesvirus 4,Infectious Mononucleosis Virus,Burkitt's Lymphoma Virus,HHV-4,Herpesvirus 4 (gamma), Human,Burkitts Lymphoma Virus,E B Virus,E-B Viruses,Epstein Barr Virus,Herpesvirus, Burkitt,Infectious Mononucleosis Viruses,Lymphoma Virus, Burkitt,Mononucleosis Virus, Infectious,Mononucleosis Viruses, Infectious
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

Y Sakai, and S Ohga, and Y Tonegawa, and H Takada, and F Nakao, and H Nakayama, and T Aoki, and S Yamamori, and T Hara
Restricted diversification of T-cells in chronic active Epstein-Barr virus infection: potential inclination to T-lymphoproliferative disease.
May 1999, American journal of hematology,
Y Sakai, and S Ohga, and Y Tonegawa, and H Takada, and F Nakao, and H Nakayama, and T Aoki, and S Yamamori, and T Hara
Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection.
June 2011, International journal of hematology,
Y Sakai, and S Ohga, and Y Tonegawa, and H Takada, and F Nakao, and H Nakayama, and T Aoki, and S Yamamori, and T Hara
A case of severe chronic active Epstein-Barr virus infection with T-cell lymphoproliferative disorder.
June 2004, The Korean journal of internal medicine,
Y Sakai, and S Ohga, and Y Tonegawa, and H Takada, and F Nakao, and H Nakayama, and T Aoki, and S Yamamori, and T Hara
Vidarabine therapy for severe chronic active Epstein-Barr virus infection.
January 2001, Journal of pediatric hematology/oncology,
Y Sakai, and S Ohga, and Y Tonegawa, and H Takada, and F Nakao, and H Nakayama, and T Aoki, and S Yamamori, and T Hara
An adult case of severe chronic active Epstein-Barr virus infection with T-cell lymphoproliferative disorder.
December 2012, The Korean journal of internal medicine,
Y Sakai, and S Ohga, and Y Tonegawa, and H Takada, and F Nakao, and H Nakayama, and T Aoki, and S Yamamori, and T Hara
Chronic, active Epstein-Barr virus infection.
January 2000, Current opinion in hematology,
Y Sakai, and S Ohga, and Y Tonegawa, and H Takada, and F Nakao, and H Nakayama, and T Aoki, and S Yamamori, and T Hara
'Chronic active Epstein-Barr virus infection'.
August 1987, JAMA,
Y Sakai, and S Ohga, and Y Tonegawa, and H Takada, and F Nakao, and H Nakayama, and T Aoki, and S Yamamori, and T Hara
Chronic active Epstein-Barr virus infection.
October 2020, Blood,
Y Sakai, and S Ohga, and Y Tonegawa, and H Takada, and F Nakao, and H Nakayama, and T Aoki, and S Yamamori, and T Hara
[Chronic active Epstein-Barr virus infection].
December 2011, Uirusu,
Y Sakai, and S Ohga, and Y Tonegawa, and H Takada, and F Nakao, and H Nakayama, and T Aoki, and S Yamamori, and T Hara
Epstein-Barr virus-positive cytotoxic T-cell lymphoma followed by chronic active Epstein-Barr virus infection-associated T/NK-cell lymphoproliferative disorder: a case report.
December 2013, Human pathology,
Copied contents to your clipboard!